MONCTON, N.B. – Technology from the Atlantic Cancer Research Institute in Moncton is going to be commercialized for the first time.
ACRI president Doctor Rodney Ouellette says the technology will allow researchers and clinicians to more easily extract diagnostic information on potential disease cells through a quick and simple blood, urine or saliva test.
Ouellette says it’s a way of getting at diagnostic material without necessarily having to perform a biopsy.
The potential applications also reach to neurological diseases, prenatal diagnosis and immunological diseases.
The technology, a sythetic peptide called VN96, is going to be licenced to New England Peptide which will produce it in a kit form and market it worldwide.